This article is more than 5 years old. Information may no longer be current.
Novaliq agent improves corneal staining at 8 weeks
Novaliq announced that phase 2 clinical trial results from its SEECASE study for the treatment of dry eye and meibomian gland dysfunction with NOV03 met its primary endpoint for improvement of total corneal fluorescein staining over control at 8 weeks.
SEECASE was a phase 2, multicenter, randomized, double-masked, saline-controlled clinical trial designed to evaluate the effects of NOV03, a preservative-free ophthalmic solution, at two different dosing regimens on signs and symptoms of dry eye disease.
The treatment effect started as early as 2 weeks after start of treatment and was maintained over the entire duration of the trial, for both treatment regimens, according to Novaliq in a press release.
NOV03 also showed pronounced and highly statistically significant improvements in various symptoms over control, consistent throughout the entire trial.
NOV03 treats dry eye disease associated with MGD based on novel modes of action that balance the tear condition. It stabilizes the lipid layer for several hours, thereby preventing excessive evaporation, and has the potential to penetrate the meibomian glands, improve meibum quality and enhance the function of the meibomian gland, according to the press release.